Competing sponsors share one control arm in the same indication
Three companies testing three drugs against the same standard treatment each recruit their own control group. Pooling those controls in one shared study would need fewer patients and answer faster.
A neutral academic sponsor runs a master protocol in a defined indication with a single concurrent control arm; each company adds its experimental arm under a pre-agreed data-access and publication charter, paying a per-patient fee. Randomisation is concurrent, so this is a true RCT for each comparison. Precedents include the Lung-MAP and I-SPY structures, but industry-led registrational use is rare.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA standing platform trial for every major cancer, funded as infrastructure
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Trial design, endpoints and cost, Pancreatic ductal adenocarcinoma.
- IdeaA standing platform trial that assigns treatment by how the tumour escaped
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Trial design, endpoints and cost.
- IdeaA permanent platform trial for supportive-care interventions inside cooperative groups
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost.
- IdeaBorrow from past control arms to shrink the control group in phase 3
Shares Trials enrol too few, too slowly, Trial design, endpoints and cost, Non-small-cell lung cancer.
- IdeaShared concurrent control arms across sponsors' trials in the same setting
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Pancreatic ductal adenocarcinoma.
- IdeaA shared library of pooled control arms to shrink and speed future trials
Shares Secrecy and intellectual property block collaboration, Trials enrol too few, too slowly, Trial design, endpoints and cost.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares Secrecy and intellectual property block collaboration, Basket, umbrella, and platform trials, Trial design, endpoints and cost, Pancreatic ductal adenocarcinoma.
- IdeaPoint-of-care randomisation built into the oncology record
Shares Trials enrol too few, too slowly, Trial design, endpoints and cost.